CSS
PGNX

Cubist Systematic Strategies’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cubist Systematic Strategies’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,126
Closed -$62K – 2627
2019
Q2 		$62K Buy
10,126
+9,600
+1,825% +$46.3K ﹤0.01% 2298
2019
Q1 		$2K Sell
526
-6,369
-92% -$28.8K ﹤0.01% 2210
2018
Q4 		$29K Buy
+6,895
New +$35.1K ﹤0.01% 1926
2018
Q1 		– Sell
-26,747
Closed -$159K – 2177
2017
Q4 		$159K Buy
+26,747
New +$162K 0.01% 1604
2017
Q2 		– Sell
-37,749
Closed -$356K – 1968
2017
Q1 		$356K Buy
+37,749
New +$377K 0.03% 819
2016
Q4 		– Sell
-1,937
Closed -$12K – 1973
2016
Q3 		$12K Buy
+1,937
New +$11.7K ﹤0.01% 1635
2015
Q4 		– Sell
-29,982
Closed -$171K – 2048
2015
Q3 		$171K Sell
29,982
-104,340
-78% -$801K 0.01% 1517
2015
Q2 		$1M Buy
+134,322
New +$813K 0.05% 563

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Cubist Systematic Strategies's PGNX Position: Q3 2019 in Review

Cubist Systematic Strategies sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 10,126 shares — an estimated $62K sold.

Cubist Systematic Strategies first reported a position in PGNX in Q2 2015 and held it in 8 quarters. The position peaked at $1M in Q2 2015. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

  • Cubist Systematic Strategies reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
  • Cubist Systematic Strategies sold 10,126 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $62K.
  • Cubist Systematic Strategies first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 8 quarters.
  • Cubist Systematic Strategies's Progenics Pharmaceuticals Inc position peaked at $1M in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Cubist Systematic Strategies's 13F filing for Q3 2019, filed 14 Nov 2019.